Regenxbio (RGNX) Misses Q3 EPS by 5c

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.17), $0.05 worse than the analyst estimate of ($1.12). Revenue for the quarter came in at $24.19 million versus the consensus estimate of $23.63 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Jefferies says Europe battery electric vehicle sales jump in May
• Rocket Lab USA, Inc. (RKLB) June 26 weekly 120 and 125 calls active, share price down 6%